SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase I Safety and Tolerability of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC)

  • Org Study ID: VX0116
  • Secondary ID:
  • NCT ID: NCT03854721
  • NCT Alias:
  • Sponsor: Vaxiion Therapeutics - Industry
  • Source: Vaxiion Therapeutics

Brief Summary

The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for Instillation (VAX014) in patients with low-grade Non-Muscle Invasive Bladder Cancer (NMIBC). VAX014 is a targeted oncolytic agent designed to kill tumor cells following instillation into the urinary bladder.

Detailed Description

This study will evaluate the safety and tolerability of VAX014 using a 3+3 dose escalation
design to determine a maximum tolerated dose (MTD) followed by a dose expansion at the
Recommended Phase 2 Dose (RP2D). Both phases of the study will use a Window of Opportunity
study design where patients with a single, low-grade Ta lesion will receive VAX014 via a
urinary catheter into the bladder, weekly for 6 weeks prior to undergoing Transurethral
Resection of Bladder Tumor (TURBT) to assess antitumor activity against the mapped lesion.

Patients enrolled in this study must have low-grade (Ta) Non-Muscle Invasive Bladder Cancer.
However, eligible patients may have up to 5 low-grade Ta lesions at screening, and all but a
single mapped lesion will be resected prior to receiving VAX014. The mapped lesion is
assessed for anti-tumor activity.

VAX014 is a formulation of recombinant bacterial minicells which is designed to selectively
target two NMIBC-associated integrin heterodimers to de-stabilize tumor cell membranes, with
the result being tumor cell lysis.

Overal Status Start Date Phase Study Type
Recruiting May 10, 2019 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Maximum tolerated dose (MTD) of VAX014

Primary Outcome 1 - Time Frame: up to 28 days

Primary Outcome 2 - Measure: Incidence of Treatment-Emergence Adverse Events (Safety and Tolerability)

Primary Outcome 2 - Time Frame: Through study completion, an average of 20 weeks


  • Urothelial Carcinoma of the Urinary Bladder


Inclusion Criteria:

1. Signed, informed consent

2. Age 18 or more years

3. Pathologically confirmed low-grade Ta urothelial carcinoma (UC) of the urinary bladder

4. NMIBC with one solitary measurable tumor at the start of study, measuring ≥ 5 mm and ≤
15 mm in greatest diameter (up to 4 additional low-grade Ta lesions, each measuring no
more than 15 mm may be removed at screening provided a single lesion remains)

5. Treatment-naïve or failed one previous regimen of intravesical therapy (BCG or

6. If recurrent disease, then more than 6 months from prior resection, more than 3 months
from completion of last intravesical therapy with BCG, and more than 6 weeks from
completion of last therapeutic intravesical therapy with chemotherapy

7. If previously treated, recovered from prior treatment-related toxicity to ≤ Grade 1

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 116

9. Absolute neutrophil count (ANC) ≥ 1,500/mm3

10. Platelet count ≥ 100,000/mm3

11. Total bilirubin ≤ 1.5 x upper limit of normal (ULN), or ≤ 3 x ULN in subjects with
Gilberts disease

12. Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 30 mL/min

13. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x ULN

14. Willingness to participate in collection of pharmacokinetic samples

15. Women of childbearing potential must have a negative serum pregnancy test.

16. All subjects of childbearing potential must be willing to use effective contraception
while on treatment and for 3 months after the last dose of VAX014

Exclusion Criteria:

1. Additional papillary disease at screening (in addition to the solitary low-grade Ta
lesion detailed in the inclusion criteria) that

1. Consist of 6 or more lesions

2. Consists of any lesion with a maximal diameter of greater than 15 mm

2. Confirmed or suspected perforated bladder

3. History of difficult catheterization that in the opinion of the investigator will
prevent administration of VAX014

4. Presence or history of any high-grade urothelial cancer (including CIS) or high-grade
urine cytology

5. Intravesical chemo-or biological therapy within 6 months of first administration of

6. UC of the ureters or urethra

7. History of interstitial cystitis

8. History of radiation to the pelvis

9. History of vesicoureteral reflux or an indwelling urinary stent

10. Other known active cancer(s) likely to require treatment or interfere with study
objectives over the next two (2) years

11. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic

12. Known HIV, Hepatitis B, or Hepatitis C infection

13. Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial
infarction within 6 months)

14. Major surgery other than diagnostic surgery within 4 weeks of first administration of

15. Pregnant or currently breast-feeding

16. Psychiatric illness/social situations that would interfere with compliance with study

17. Presence of any sessile appearing tumor suspected of being invasive or high-grade
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Contact

Name: Jennifer Schulz

Phone: 858-630-1952



Facility Status Contact
The Urology Center of Colorado
Denver, Colorado 80211
United States
Recruiting Robin Dorsey, BA, CCRC
University of Iowa Hospital and Clinics
Iowa City, Iowa 52242
United States
Recruiting Mary E Schall
New Jersey Urology, LLC.
Edison, New Jersey 08837
United States
Recruiting Haleema Hameed, Sr. CRC
Carolina Urologic Research Center
Myrtle Beach, South Carolina 29572
United States
Recruiting Stacy Rust, RMA, CRC
Baylor College of Medicine
Houston, Texas 77030
United States
Recruiting Sharon Harrison